- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05378646
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis (ING-HP-1)
An Open Controlled Study of the Efficacy and Safety of Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Literature data and the results of preclinical studies of interferon-gamma, as well as the features of the immunopathogenesis of chronic prostatitis, show the expediency of studying the use of Ingaron in this pathology.
The study was conducted to compare the efficacy and safety of Ingaron in combination with standard therapy with its subcutaneous administration and standard therapy in patients with chronic prostatitis.
The study was planned to include 50 male patients aged at least 18 years with a confirmed diagnosis of chronic prostatitis.
In the course of the study, Ingaron was administered at a dose of 500,000 IU once a day, every other day. In addition to Ingaron, patients received antibiotic therapy, anti-inflammatory drugs, alpha-blockers (if necessary). Magnetic laser therapy and prostate massage were also provided.
The patients were divided into 2 groups: main and control.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age at least 18 years old (at the time of inclusion).
- Objectively confirmed diagnosis of chronic prostatitis at the time of inclusion in the study (more than 10 leukocytes / field of view in cytological examination of prostate secretion; more than 1x10^5 CFU in bacteriological examination of prostate secretion (regardless of the nature of the inoculated microflora)).
- Concomitant myco-, ureaplasma, gardnerella, chlamydial, urogenital viral infection is not excluded.
- The volume of residual urine (Q max) is not more than 70 ml.
- The maximum urination rate, according to urofluometry, is not less than 10 ml / sec.
- Allowed previous therapy of chronic prostatitis, not less than 30 days after the end of the last course of treatment.
- If there is a history of surgical treatment for benign prostatic hyperplasia, the time from the moment of surgery to inclusion in the study is at least 6 months.
- Availability of written informed consent to participate in the clinical study.
Exclusion Criteria:
- Positive test results for syphilis (Wasserman reaction), hepatitis (HbsAg, anti-HCV), HIV infection.
- Known allergic reactions to interferons, or other significant allergic diseases.
- A history of autoimmune disease.
- The presence of external drains of the organs of the genitourinary system.
- The presence of histologically proven prostate cancer.
- A history of diabetes mellitus.
- Any immunotropic therapy within the last 6 weeks prior to enrollment in the study.
- Condition after organ transplantation, constant intake of immunosuppressive drugs.
- Severe pathology from the cardiovascular system (uncontrolled arterial hypertension, unstable angina pectoris, congestive heart failure, cardiac arrhythmias), a history of myocardial infarction or cerebrovascular accident within the last 6 months.
- Severe pathology of the liver (increased content of AST, ALT 2 times higher than the upper limit of the norm, the content of total bilirubin> 2 mg / dl), kidney (creatinine content> 1.5 mg / dl); signs of hepatic and / or renal failure.
- Other serious (acute or chronic) pathological conditions, including mental illness, as well as abnormalities in laboratory parameters, which, in the opinion of the investigator, may increase the risk associated with participation in the study or affect the interpretation of the efficacy and safety data obtained in this research.
- Alcohol and / or drug dependence.
- Participation in other clinical trials in the last 3 months prior to inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Patients received Ingaron 500,000 IU subcutaneously once a day, every other day.
The course of treatment is 7 injections.
The first injection was given on the first day of active therapy.
Subsequent injections were given every other day.
The period of active therapy was 14 days.
|
received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
Other Names:
|
No Intervention: Control
Patients received standard treatment for chronic prostatitis.
The period of active therapy was 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dynamics of the total score and improvement in the quality of life on the scale IPSS.
Time Frame: Day 13
|
The sum of points was assessed, as well as the symptom complex on the basis of the "IPSS" questionnaire - the international system for the total assessment of symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms was assessed from 0 to 6 points. symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms is rated from 0 to 6 points. |
Day 13
|
Immunohistochemical study of prostate secretion with assessment of cytological parameters.
Time Frame: Day 14
|
Content of polymorphonuclear leukocytes in prostate secretion.
|
Day 14
|
Immunohistochemical study of prostate secretion with assessment of cytological parameters.
Time Frame: Day 14
|
The content of lymphocytes in prostate secretion.
|
Day 14
|
Evaluation of cytological parameters of prostate secretion.
Time Frame: Day 14
|
The number of lecithin grains.
|
Day 14
|
Evaluation of cytological parameters of prostate secretion.
Time Frame: Day 14
|
The number of epithelial cells.
|
Day 14
|
Microscopy of prostate secretion and immunohistochemical study of prostate secretion with assessment of cytological parameters.
Time Frame: Day 14
|
The effect of interferon-gamma on T-lymphocytes.
|
Day 14
|
Evaluation of cytological parameters of prostate secretion.
Time Frame: Day 90
|
The content of polymorphonuclear leukocytes in prostate secretion.
|
Day 90
|
Immunohistochemical study of prostate secretion with assessment of cytological parameters.
Time Frame: Day 90
|
The content of lymphocytes in prostate secretion.
|
Day 90
|
Evaluation of cytological parameters of prostate secretion.
Time Frame: Day 90
|
The number of lecithin grains.
|
Day 90
|
Evaluation of cytological parameters of prostate secretion.
Time Frame: Day 90
|
The number of epithelial cells.
|
Day 90
|
Microscopy of prostate secretion and immunohistochemical study of prostate secretion with assessment of cytological parameters.
Time Frame: Day 90
|
The effect of interferon-gamma on T-lymphocytes.
|
Day 90
|
Evaluation of indicators of urination. Ultrasound of the prostate gland.
Time Frame: Day 90
|
Ultrasound of the prostate gland.
|
Day 90
|
Evaluation of indicators of urination. Urofluometry.
Time Frame: Day 90
|
Urofluometry.
|
Day 90
|
Evaluation of indicators of urination. General urine analysis.
Time Frame: Day 90
|
General urine analysis.
|
Day 90
|
Evaluation of the inter-relapse period. Identification of an exacerbation of a chronic process.
Time Frame: Month 3
|
Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period.
|
Month 3
|
Evaluation of the inter-relapse period. Identification of signs of a relapse of the disease.
Time Frame: Month 3
|
Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period.
|
Month 3
|
Evaluation of the inter-relapse period. Identification of an exacerbation of a chronic process.
Time Frame: Month 6
|
Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period.
|
Month 6
|
Evaluation of the inter-relapse period. Identification of signs of a relapse of the disease.
Time Frame: Month 6
|
Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period.
|
Month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Leonid Apanansky, Master, SPP Pharmaclon Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ING-HP-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Prostatitis
-
Ain Shams UniversityCompletedDutasteride | Category IIIB Chronic ProstatitisEgypt
-
National Institute of Diabetes and Digestive and...CompletedChronic Prostatitis With Chronic Pelvic Pain Syndrome
-
Aziende Chimiche Riunite Angelini Francesco S.p.AHippocrates ResearchCompleted
-
University of Roma La SapienzaCompleted
-
Adrian GasparCompletedChronic Prostatitis With Chronic Pelvic Pain Syndrome | ProstatodyniaArgentina
-
The Krongrad InstituteUnknownProstatitis | Chronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
-
Cairo UniversityUnknownChronic Non Bacterial Prostatitis
-
Second Affiliated Hospital, School of Medicine,...Peking University First Hospital; Changhai Hospital; First Affiliated Hospital... and other collaboratorsUnknown
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCystitis, Interstitial | Painful Bladder Syndrome | Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Bacterial Prostatitis | Asymptomatic Inflammatory ProstatitisUnited States
-
Shanghai University of Traditional Chinese MedicineHuashan HospitalActive, not recruitingChronic Prostatitis With Chronic Pelvic Pain SyndromeChina
Clinical Trials on Interferon gamma human recombinant (IFN-G)
-
SPP Pharmaclon Ltd.CompletedCOVID-19 Respiratory InfectionRussian Federation
-
SPP Pharmaclon Ltd.CompletedHuman Papillomavirus Infection | Anogenital WartsRussian Federation
-
SPP Pharmaclon Ltd.CompletedCOVID-19 Respiratory Infection | Acute Respiratory DiseaseRussian Federation
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.TerminatedMyxoid Liposarcoma | Synovial Sarcoma | Round Cell LiposarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
SPP Pharmaclon Ltd.RecruitingPulmonary TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.CompletedCommunity-acquired PneumoniaRussian Federation
-
SPP Pharmaclon Ltd.RecruitingRespiratory TuberculosisRussian Federation
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Vidara Therapeutics Research LtdCompleted